McKinsey January 9, 2025
Leading biopharmaceutical companies manage their clinical pipelines to optimize for risk and reward. Here’s how.
Discovering and developing effective new medicines has always been difficult—but it is particularly hard today. The world’s biopharmaceutical companies face challenges ranging from rising R&D costs to the evolving impact of the US Inflation Reduction Act, all while focused on delivering innovative solutions for patients. Yet leading companies remain effective despite these pressures, with the past few years seeing the emergence of innovative modalities and novel mechanisms of action (MoAs) that can better treat patients in areas with high levels of unmet medical needs. We examined what can be learned from their approaches and identified three actions leaders are taking to better position their portfolios:
...Today's Sponsors
Today's Sponsor
